Timeline

Catherine Blanc

Technician

30 Aug 2025

publication

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses

04 Jul 2025

publication

Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.

21 Jun 2024

publication

Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus.

10 Jun 2024

publication

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

01 Dec 2023

publication

TMPRSS2 is a functional receptor for human coronavirus HKU1.

07 Sep 2023

publication

Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.

01 Jan 2023

publication

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.

14 Sep 2022

publication

A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity.

26 Jul 2022

publication

A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity.

27 Apr 2022

publication

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

07 Dec 2021

publication

Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

29 Jul 2021

team

Institut Pasteur-TheraVectys Joint Laboratory

24 Apr 2018

publication

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors

01 Jun 2014

publication

Misidentification of Saprochaete clavata as Magnusiomyces capitatus in clinical isolates: utility of internal transcribed spacer sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry and importance of reliable databases.

A little guide for advanced search:

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses

Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.

Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus.

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

TMPRSS2 is a functional receptor for human coronavirus HKU1.

Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.

A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity.

A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity.

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Institut Pasteur-TheraVectys Joint Laboratory

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors

Misidentification of Saprochaete clavata as Magnusiomyces capitatus in clinical isolates: utility of internal transcribed spacer sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry and importance of reliable databases.